Conv. Plasma
Nigella Sativa
Vitamin A
Vitamin C
Vitamin D

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Sawanpanyalert68%0.32 [0.15-0.66]progressionn/an/aTau​2 = 0.00; I​2 = 0.0%Early treatment48%0.52 [0.36-0.76]4/2314/17948% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Shinkai (SB RCT)37%0.63 [0.40-0.98]imp. time107 (n)49 (n)Alotaibi57%0.43 [0.18-1.01]death244 (n)193 (n)OT​1Tau​2 = 0.08; I​2 = 61.3%Late treatment26%0.74 [0.57-0.95]154/902153/1,67626% improvementAll studies32%0.68 [0.54-0.86]158/1,133157/1,85532% improvement13 favipiravir COVID-19 Oct 17, 20211 OT: comparison with other treatmentTau​2 = 0.08; I​2 = 57.0%; Z = 3.21Effect extraction pre-specifiedFavors favipiravirFavors control
Database of all favipiravir COVID-19 studies. Submit updates/corrections.
Restrict:    All    Early    Late
Sep 14
Late Alotaibi et al., International Journal of General Medicine, 2021:14 (Peer Reviewed) death, ↓57.2%, p=0.05 Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Details   Retrospective hospitalized patients in Saudi Arabia, showing lower mortality with favipiravir compared to HCQ, not quite reaching statistical significance. Authors do not indicate the factors behind which therapy was chosen. Confounding b..
Sep 9
Early Sawanpanyalert et al., Southeast Asian Journal of Tropical Medicine and Public Health, 52:4 (Peer Reviewed) progression, ↓68.0%, p=0.003 Assessment of outcomes following implementation of antiviral treatment guidelines for COVID-19 during the first wave in Thailand
Details   Retrospective 744 hospitalized patients in Thailand, showing lower risk of a poor outcome for favipiravir treatment within 4 days of symptom onset. Early treatment with CQ/HCQ and lopinavir/ritonavir or darunavir/ritonavir also showed low..
Aug 27
Late Shinkai et al., Infectious Diseases and Therapy, doi:10.1007/s40121-021-00517-4 (Peer Reviewed) no recov., ↓37.1%, p=0.01 Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Details   RCT 156 patients in Japan, 107 treated with favipiravir, showing significant improvement in a composite outcome defined as the time to improvement in temperature, SpO2, CT findings, and recovery to PCR-.
Aug 24
Late Almoosa et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.022 (Peer Reviewed) death, ↑42.3%, p=0.10 Favipiravir versus Standard of Care in Patients with Severe COVID-19 Infections: A Retrospective Comparative Study
Details   Retrospective 226 COVID-19 pneumonia patients, 110 treated with favipiravir, showing higher mortality (p=0.1) and ICU admission (p=0.02) with treatment in multivariate analysis.
Apr 29
Late Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 (Peer Reviewed) death, ↓26.1%, p=0.28 Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19
Details   Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
Apr 21
Late Zhao et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702 (Peer Reviewed) viral+, ↓59.0%, p=0.06 Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial
Details   RCT with 55 patients (36 favipiravir, 19 control) who were PCR+ after recovery, showing improved viral clearance with treatment.
Apr 19
Late Favipiravir Observational Study Group, Fujita Health University (Preprint) Favipiravir Observational Study Interim Report 3
Details   Retrospective analysis of favipiravir use in 10,986 hospitalized patients, including analysis of changes in clinical status and side effects. Common adverse events were uric acid level increase and liver function enzyme increase. Authors ..
Apr 17
Early Fujii et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013 (Peer Reviewed) Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
Details   Retrospective 41 favipiravir patients finding that early treatment was more successful.
Mar 11
Late Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522 (Peer Reviewed) death, ↑19.2%, p=0.54 Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Details   RCT late stage patients (median SpO2 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.
Mar 8
Late Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Details   Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study.
Feb 4
Early, Late Uçan et al., Research Square, doi:10.21203/ (Preprint) Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Details   Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV,..
Jan 25
Early Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9 (Peer Reviewed) death, ↓45.5%, p=0.12 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Details   RCT with 44 favipiravir patients and 48 CQ patients, showing non-statistically significant lower mortality, ventilation, and hospitalization time with favipiravir.
Jan 14
Early Karatas et al., Research Square, doi:10.21203/ (Preprint) Early Onset Favipiravir Saves Lives
Details   Retrospective 180 hospitalized patients showing lower mortality when Favipiravir is given earlier. 17% of patients given Favipiravir within 3 days died, compared to 38% when given after 3 days.
Nov 17
Late Doi et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01897-20 (Peer Reviewed) A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Details   Small RCT comparing late and very late (7 and 14 days from fever onset) favipiravir. Viral clearance was non-statistically significantly improved with relatively early treatment. There was a reduction in time to defervescence, and a signi..
Nov 16
Early Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142 (Peer Reviewed) recov. time, ↓40.0%, p=0.03 Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
Details   RCT with 75 favipiravir patients and 75 control patients showing reduced time to clinical cure and reduced time of viral shedding.
Nov 9
Late Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008 (Peer Reviewed) Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
Details   Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
Nov 5
Late Pushkar et al., NCT04542694 (Preprint) no recov., ↓14.1%, p=0.06 Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Details   RCT 200 patients showing improvements in clinical recovery and viral clearance with favipiravir. There is no paper available but results are posted in
Oct 26
Early Ruzhentsova et al., SSRN, doi:10.2139/ssrn.3696907 (Preprint) hosp., ↓6.0%, p=0.49 Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
Details   RCT 168 patients, 112 receiving favipiravir and 56 SOC, showing shorter time to clinical improvement and faster viral clearance with favipiravir.
Sep 30
Late Zhaao et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2020.110825 (Peer Reviewed) Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Details   Small study with 14 combined favipiravir/tocilizumab, 7 favipiravir, and 5 tocilizumab patients suggesting that tocilizumab combined with or without favipiravir can improve pulmonary inflammation and inhibit progression.
Aug 9
Late Ivashchenko et al., Clin. Infect. Dis., doi:10.1093/cid/ciaa1176 (Peer Reviewed) viral+, ↓46.4%, p=0.03 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Details   Intermin results for a small RCT with 40 favipiravir and 20 control patients showing faster viral clearance with favipiravir. There is limited data in this report to evaluate the results. The report indicates that 75% of the control group..
Mar 18
Late Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007 (Peer Reviewed) pneumonia, ↓68.7%, p=0.04 Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Details   Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.